Use of oxycodone controlled-release immediately after NSAIDs: A new approach to obtain good pain control

Leopoldo Tessaro, E. Bandieri, G. Costa, G. Fornasier, V. Iorno, C. Pizza, G. Pastacaldi, G. Micheletto

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Opioids are recommended as appropriate therapy for the treatment of cancer pain and chronic non-malignant pain. Oxycodone is an alternative agent to its parent compound, morphine, and is available in a controlled-release (CR) formulation that allows convenient twice-daily dosing. The aim of this study was to evaluate the efficacy and tolerability of oxycodone CR as first-line therapy in patients with chronic cancer or non-cancer pain that was not relieved by non-steroidal anti-inflammatory drugs (NSAIDs). Methods: This was a prospective, open-label, multicentre trial carried out in 8 pain and oncology centres in Italy. Patients (n=309) with NSAID-refractory chronic cancer (55.7%), non-cancer (39.4%) or mixed (4.9%) pain (rating of 4-10 on a numerical rating scale [NRS] from 0-10) were enrolled. Patients were treated with oral oxycodone CR twice daily for at least 28 days. Dosage was individualized for each patient and up-titrated over the first week of treatment. The primary endpoint was reduction in NRS score for pain. Secondary endpoints were tolerability, quality of life and patient assessment of treatment efficacy. Results: A significant decrease (57%) in pain intensity was recorded during the first week of therapy (decrease in NRS score from 7.85 ± 1.4 to 3.35 ± 1.8; p

Original languageEnglish
Pages (from-to)113-121
Number of pages9
JournalEuropean Review for Medical and Pharmacological Sciences
Volume14
Issue number2
Publication statusPublished - Feb 2010

Keywords

  • Analgesia
  • Cancer pain
  • Chronic pain
  • NSAID-refractory pain
  • Oxycodone controlled release (CR)

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Use of oxycodone controlled-release immediately after NSAIDs: A new approach to obtain good pain control'. Together they form a unique fingerprint.

Cite this